Quidel Corporation

Seite 1 von 1
Neuester Beitrag: 10.05.21 09:33
Eröffnet am:02.01.04 17:10von: EskimatoAnzahl Beiträge:8
Neuester Beitrag:10.05.21 09:33von: sonnenschein.Leser gesamt:5.619
Forum:Börse Leser heute:1
Bewertet mit:


3947 Postings, 8146 Tage EskimatoQuidel Corporation

02.01.04 17:10
Schönes Wochenende, Gruss E.


Zacks.com Announces that David Nichols Highlights the Following Stocks: Health Management Associates, Province Healthcare, and Quidel Corporation  
Monday, December 22, 2003 06:00 AM ET  Printer-friendly version  
CHICAGO--(BUSINESS WIRE)--Dec. 22, 2003--The new Medicare law will have a positive impact on certain healthcare stocks, says David Nichols, who puts a focus on three companies that could give your portfolio a shot-in-the-arm. Learn about Health Management Associates, Inc. (NYSE: HMA, news), Province Healthcare Company (NYSE: PRV, news), and Quidel Corporation (NASDAQ: QDEL, news). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84

Here are the highlights from the Featured Expert column:

A watershed event like the new law overhauling Medicare is bound to affect more than just one sector. Most of the attention is going to the $400 billion prescription drug benefit that stretches out over the next 10 years, which should give some generic drug companies a shot in the arm, so to speak. Less well known is that the bill expands funding to hospitals by $25 billion over that period, offering important revenue-enhancing incremental reimbursements and making some hospital companies a buy. Also benefiting will be some medical diagnostics companies.

Several hospital chains serve primarily non-urban populations; two are Health Management Associates, Inc. (NYSE: HMA, news) and Province Healthcare. Health Management's hospitals provide general acute care health services and numerous specialty services in non-urban communities mainly in the southeast and southwest. The company operates or leases over 50 hospitals with more than 7,500 beds, and two psychiatric- only hospitals. By next month, it will have acquired 10 hospitals in 2003 alone. Its fourth-quarter earnings per share are up four cents from a year ago, even in a year marked by heavy acquisition activity. Net income was up 16% to about $70 million on net patient-service revenue that grew 11% to $657 million. "Same-store" revenues, meaning hospitals owned or operated by the company for a year or more, were up an impressive 7.8%; this represents HMA's 60th consecutive quarter of same hospital revenue growth.

Also in a position to benefit from increased rural spending is Province Healthcare Company (NYSE: PRV, news). Province takes a slightly different approach from Health Management. Like HMA, it owns and operates hospitals in non-urban markets -- some 20 general acute care hospitals in 13 states with a total of 2,284 licensed beds. The main difference is that Province is also in the hospital management business, managing for a fee 37 hospitals it doesn't own, with over 4,000 licensed beds. Earnings per share in its latest quarter were up a penny, operating revenues increased 6% to $195 million, net income was up 4% to $9.8 million, admissions and outpatient revenue were up.

Despite the high P/E and pint-sized volume, Quidel Corporation (NASDAQ: QDEL, news) could reward the patient investor. Quidel develops and manufactures rapid diagnostics -- point-of-care tests used in doctors' offices, hospitals and clinical labs to quickly and inexpensively diagnose pregnancy, streptococcus-A, two types of flu, bacteria-related ulcers, bone conditions, and certain urinary and auto-immune infections. Given world health conditions and industrialized-nation demographics, all are growing markets. Revenue for the third quarter was up 28% to $18.6 million. Restructuring expenses and LTF development led to a net loss of $500,000 or 2 cents a share, although well down from its net loss in last year's third quarter; gross margins and cash were both up. Tight cost controls, effective restructuring, growing revenues and cutting-edge products make a small stake in Quidel worth taking.

Learn a lot more about these companies, and don't forget to read David Nichols' market forecast and get even more recommendations by clicking: http://at.zacks.com/?id=85

About Zacks Featured Experts


3947 Postings, 8146 Tage EskimatoUpdate.

12.02.04 02:22
Quidel ups 2004 forecast, shares rise more than 5% (5:16 PM ET) SAN FRANCISCO (CBS.MW) -- Quidel(QDEL: news, chart, profile)share gained more than 5 percent late Wednesday after the company upped its 2004 forecast. The diagnostic test maker said it expects to report earnings of 39-44 cents a share on sales of $104 million to $109 million, vs. a previous forecast of 38-41 cents a share on sales of $100 million. Quidel reported a profit of $18.8 million, or 59 cents a share, on sales of $33.2 million for the fourth quarter. Last year, the firm made $1 million, or 3 cents a share, on sales of $22.8 million. Quidel also said that chairman Andre de Bruin would not seek re-election. The stock added 70 cents in late dealings, to $13.75.

Gruss E.


159 Postings, 3523 Tage TigerEye2000Nur 2

16.10.20 12:33
und sehr alte Beiträge bei einem spannenden Wert.
Da ist keiner drin :-) sehr gutes Zeichen  

523 Postings, 1348 Tage cosmocSchade

09.11.20 15:16
Hatten den Wert mir auch schon angesehen, aber wenn er so hart abgestraft wird, baut es nicht wirklich Vertrauen auf, dass es die Margen auch nach Corona aufrecht erhalten kann.  

71 Postings, 2777 Tage Bulle1006Auch dabei...

12.12.20 16:56
Hallo,bin am Freitag rein Spekulativ zu 168,00 rein. Mein Ziel sind 200,00 Ende des Jahres. Bin durch Zufall auf den hoch interessanten Wert aufmerksam geworden. Enorme Wachstumschancen, auch nach Corona.


36 Postings, 3275 Tage paladiusNn

18.12.20 21:14
Weiß einer warum es die letzten Tage so fällt?  

10826 Postings, 2178 Tage VassagoQDEL 112$

23.04.21 16:01
Der vorläufige Umsatz im ersten Quartal belief sich auf 374-376 Mio. $, was einem Anstieg von geschätzten 114% gegenüber dem Vorjahreszeitraum entspricht. Die vorläufigen zahlen blieben jedoch hinter der Konsensschätzung von 465,7 Mio.  $ zurück.

Die "Umsatz-Schwäche" war nach Angaben des Unternehmens auf geringere Umsätze mit Influenza und anderen Produkten für Atemwegserkrankungen zurückzuführen, da keine  große "Grippewelle" vorhanden war.


10805 Postings, 4744 Tage sonnenscheinchendas Hauptprodukt sind Antikörpertest.

10.05.21 09:33
Mit einem guten Teil der Bevölkerung geimpft oder genesen, dürfte dieser Test zunehmend sinnlos sein, weil immer mehr Leute Antikörper haben werden.  

   Antwort einfügen - nach oben